ライフサイエンスコーパス: anabolic agent

1 ipidemic drug, has been identified as a bone anabolic agent.

2 s for muscle growth during administration of anabolic agents.

3 or use in hormone replacement therapy and as anabolic agents.

4 s, but there is a clinical need for new bone-anabolic agents.

5 molecular target for identification of bone anabolic agents.

6 Anabolic agents act by stimulating new bone formation.

7 Growth hormone is a potent anabolic agent and salutary modulator of posttraumatic m

8 t human PTH(1-34), is likely to be the first anabolic agent approved for treating osteoporosis, despi

9 more effective resorption inhibitors and new anabolic agents are discussed.

10 nd VC, processes ameliorated by the skeletal anabolic agent BMP-7, in part through deposition of phos

11 rathyroid hormone (PTH) is an effective bone anabolic agent, but it must be administered parenterally

12 mbination of an antiresorptive agent with an anabolic agent could be more potent than either agent al

13 substances, including stimulants, narcotics, anabolic agents, diuretics, peptides, and glycoprotein h

14 c modulators have the potential to act as an anabolic agent for the treatment of osteoporosis.

15 To date control strategies in detecting anabolic agents for promoting growth of food producing a

16 lead structure for the design of novel, bone anabolic agents for the treatment of bone disorders such

17 evaluation of a new class of potential bone anabolic agents for the treatment of osteoporosis is des

18 ors of the Wnt pathway have been proposed as anabolic agents for the treatment of osteoporosis or oth

19 templates for the development of novel bone anabolic agents for the treatment of osteoporosis.

20 echnologies--such as stem cell therapy, bone anabolic agents, genetic approaches, and nanomaterials--

21 gility in DS and identify PTH as a potential anabolic agent in the adult low bone mass DS population.

22 model amphiphilic peptide), is a potent bone anabolic agent in vivo.

23 Novel anabolic agents in development include antibodies that t

24 an activin antagonist, have shown promise as anabolic agents in early human trials.

25 European Union prohibited the use of anabolic agents in food producing animals since 1988.

26 Anabolic agents increased carcass (p = 0.002) and muscle

27 ional monotherapies with antiresorptives and anabolic agents into new combination regimens.

28 However, their clinical use as bone anabolic agents is limited due to unwanted side effects,

29 exia, but, in combination with the use of an anabolic agent, it may slow or prevent muscle loss.

30 n of Rev-ErbAalpha, whereas stimulation with anabolic agents led to a decrease in expression.

31 By directly stimulating bone formation, anabolic agents might have greater potential than the an

32 The effects of cartilage catabolic and anabolic agents on the expression of Rev-ErbAalpha were

33 f physiological changes caused by the use of anabolic agents on the molecular level, for example, by

34 The endocrine and bone anabolic agent parathyroid hormone increased specialized

35 ve in supporting bone building with a potent anabolic agent; phosphate salt may be preferable in pati

36 an body mass to a minimum, administration of anabolic agents, recombinant human growth hormone, insul

37 support and pharmacologic intervention with anabolic agents such as growth hormone and insulin abrog

38 enic phospholipids alter the effects of bone anabolic agents, such as bone morphogenetic protein (BMP

39 gents are in clinical development, including anabolic agents, such as selective androgen receptor mod

40 Bone anabolic agents, such as synthetic parathyroid hormone a

41 Anabolic agents targeting the Wnt signaling pathway are

42 The introduction of parathyroid hormone, an anabolic agent that enhances bone formation, has been ac

43 e but do not eliminate risk of fractures, an anabolic agent that would increase bone mass and potenti

44 eoporosis including novel antiresorptive and anabolic agents that may become available in the coming

45 Currently, anabolic agents that promote bone formation are increasi

46 e only Food and Drug Administration-approved anabolic agent to treat osteoporosis; however, the cellu

47 ata to bring this exciting class of skeletal anabolic agents to patient care.

48 ility that the compounds may be used as bone anabolic agents to treat bone pathologies.

49 In both groups, endogenous anabolic agents were drastically decreased by 3- to 5-fo

50 ested compound 18 as the most promising bone anabolic agent, which was further evaluated for in vivo

51 The combining of anabolic agents with bisphosphonates has not improved ef

52 An orally active anabolic agent would provide a valuable alternative for